BeiGene's late stage tri­al shows promis­ing num­bers; Am­gen to study so­tora­sib dosage af­ter FDA rec­om­men­da­tion

Big Chi­nese phar­ma play­er BeiGene $BGNE is show­ing off some promis­ing num­bers from its in­ter­im analy­sis of a late-stage, head-to-head tri­al pit­ting their BTK drug Brukin­sa (zanubru­ti­nib) against Im­bru­vi­ca.

Re­port­ing on 415 of 652 pa­tients in the ALPINE study, cov­er­ing adults with re­lapsed or re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia or small lym­pho­cyt­ic lym­phoma, in­ves­ti­ga­tors say the BeiGene drug has sta­tis­ti­cal­ly sig­nif­i­cant re­sults for non-in­fe­ri­or­i­ty on ob­jec­tive re­sponse rates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.